Sun Pharma Completes $11.75B Financing Syndication for Organon Acquisition
Sun Pharma secured $11.75bn in syndicated financing for its all-cash Organon acquisition, funding the remainder from internal cash. Eight more lenders joined by 30 June, bringing the total to 11, with SBI the only Indian bank. Chairman Dilip Shanghvi signed the deal in April 2026, targeting about $12.4bn in combined annual revenue and a boost to Sun’s global biosimilars footprint.